MedPath

Lorazepam

Generic Name
Lorazepam
Brand Names
Ativan, Loreev
Drug Type
Small Molecule
Chemical Formula
C15H10Cl2N2O2
CAS Number
846-49-1
Unique Ingredient Identifier
O26FZP769L
Background

Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.

Indication

Lorazepam is FDA-approved for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia. It is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia and for the treatment of status epilepticus.

Some off-label indications of lorazepam include rapid tranquilization of an agitated patient, alcohol withdrawal delirium, alcohol withdrawal syndrome, muscle spasms, insomnia, panic disorder, delirium, chemotherapy-associated anticipatory nausea and vomiting, and psychogenic catatonia.

Associated Conditions
Agitation, Alcohol Withdrawal Delirium, Alcohol Withdrawal Syndrome, Anxiety, Anxiety Disorders, Chemotherapy-Induced Nausea and Vomiting, Delirium, Insomnia, Muscle Spasms, Panic Disorder, Psychogenic Catatonia, Status Epilepticus
Associated Therapies
Anesthetic premedication therapy

Computational Assessment of GABA Receptor Modulation in PTSD

Phase 4
Not yet recruiting
Conditions
Stress Disorders, Post-Traumatic
Interventions
Drug: Placebo tablet
First Posted Date
2025-02-28
Last Posted Date
2025-04-09
Lead Sponsor
VA Office of Research and Development
Target Recruit Count
150
Registration Number
NCT06852469
Locations
🇺🇸

VA San Diego Healthcare System, San Diego, CA, San Diego, California, United States

HPV Vaccine Reduced Dose

Phase 4
Not yet recruiting
Conditions
HPV
Interventions
First Posted Date
2025-01-29
Last Posted Date
2025-05-01
Lead Sponsor
Emory University
Target Recruit Count
100
Registration Number
NCT06799494
Locations
🇺🇸

Hope Clinic of the Emory Vaccine Center, Decatur, Georgia, United States

Acute Agitation in Emergency Psychiatry

First Posted Date
2024-12-30
Last Posted Date
2025-01-01
Lead Sponsor
Lone Baandrup
Target Recruit Count
132
Registration Number
NCT06752616
Locations
🇩🇰

Mental Health Center Copenhagen, Bispebjerg, Copenhagen N, Denmark

Prescribing Lorazepam for IUD Insertion: Pilot Feasibility Study

Phase 2
Not yet recruiting
Conditions
Pain
IUD
Interventions
First Posted Date
2024-07-11
Last Posted Date
2025-04-01
Lead Sponsor
University of Wisconsin, Madison
Target Recruit Count
25
Registration Number
NCT06496854
Locations
🇺🇸

UW Family Medicine Residency Clinics, Madison, Wisconsin, United States

Intranasal Dexmedetomidine vs. Standard of Care for Emergency Department (ED) Procedural Sedation in the Older Adult

Phase 3
Not yet recruiting
Conditions
Altered Mental Status
Interventions
First Posted Date
2024-04-17
Last Posted Date
2024-04-22
Lead Sponsor
State University of New York - Upstate Medical University
Target Recruit Count
60
Registration Number
NCT06370442

Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder

Phase 4
Recruiting
Conditions
Schizo Affective Disorder
Schizophrenia Agitation
Dexmedetomidine
Bipolar Disorder
Interventions
First Posted Date
2023-10-23
Last Posted Date
2023-10-23
Lead Sponsor
Temple University
Target Recruit Count
32
Registration Number
NCT06093451
Locations
🇺🇸

Temple University Episcopal Hospital, Philadelphia, Pennsylvania, United States

Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression

Phase 4
Recruiting
Conditions
Depression, Anxiety
Depression
Anxiety and Fear
Anxiety Disorders
Fear
Anxious Depression
Interventions
Other: Placebo
First Posted Date
2023-08-22
Last Posted Date
2024-11-01
Lead Sponsor
Laureate Institute for Brain Research, Inc.
Target Recruit Count
165
Registration Number
NCT06004115
Locations
🇺🇸

Laureate Institute for Brain Research, Tulsa, Oklahoma, United States

Therapies for Down Syndrome Regression Disorder

Phase 2
Recruiting
Conditions
Down Syndrome
Regression
Interventions
First Posted Date
2022-12-22
Last Posted Date
2025-03-27
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
66
Registration Number
NCT05662228
Locations
🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

Children's Hospital Colorado, Aurora, Colorado, United States

A Study of Mianserin in Combination With SSRIs in Depression With Sleep Problems

Phase 4
Recruiting
Conditions
Depression
Interventions
First Posted Date
2022-10-31
Last Posted Date
2024-06-27
Lead Sponsor
Zhenghui YI
Target Recruit Count
300
Registration Number
NCT05599126
Locations
🇨🇳

Shanghai Mental Health Center, Shanghai, China

Pharmacological Mechanisms of Low-intensity Focused Ultrasound for Motor Cortex Neuroplasticity

Early Phase 1
Recruiting
Conditions
Low Intensity Focussed Ultrasound
Interventions
First Posted Date
2021-06-11
Last Posted Date
2022-05-25
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
20
Registration Number
NCT04923659
Locations
🇨🇦

Toronto Western Hospital, Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath